Search This Blog

Friday, May 16, 2025

UroGen drops as FDA releases docs in advance of AdCom meeting

 UroGen's shares drop  as the FDA raises concerns about the trial design for UGN-102 bladder cancer treatment.

https://seekingalpha.com/news/4449578-urogen-drops-20-as-fda-releases-docs-in-advance-of-adcom-meeting

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.